View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by Cellular Technology Limited

HLA-class-II/Factor VIII (FVIII) Peptidomic Variation in Dendritic Cells

Free White Paper

HLA-class-II/Factor VIII (FVIII) Peptidomic Variation in Dendritic Cells

By Cellular Technology Limited

HLA-class-II/Factor VIII (FVIII) Peptidomic Variation in Dendritic Cells

By Cellular Technology Limited
Enter your details to receive the free paper:

Plasma-derived (pd) or recombinant (r) therapeutic factor VIII proteins (FVIIIs) are infused to arrest/prevent bleeding in patients with hemophilia A (PWHA). However, FVIIIs are neutralized if anti-FVIII-antibodies (inhibitors) develop.

Accumulating evidence suggests that pdFVIIIs with von Willebrand factor (VWF) are less immunogenic than rFVIIIs and that distinct rFVIIIs are differentially immunogenic. Since inhibitor development is T-helper-cell-dependent, human leukocyte antigen (HLA)-class-II (HLAcII) molecules constitute an important early determinant.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena